Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer

• Status: Completed
• Trial end date: 2020-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to evaluate the efficacy of TAS-118 plus Oxaliplatin compared with S-1 plus Cisplatin in overall survival in patients with advanced gastric cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taiho Pharmaceutical Co., Ltd.
• Collaborator: Yakult Honsha Co., LTD
• Treatments: Cisplatin; Oxaliplatin

Criteria

Key Inclusion Criteria:

• Patients who are diagnosed as gastric cancer.

• No prior treatment for gastric cancer.

• Negative or unknown for HER2 testing.

• ECOG performance status of 0 or 1.

Key Exclusion Criteria:

• Unmanageable diarrhea.

• Current peripheral sensory neuropathy or paresthesia.

• Pregnant or lactating female.